Sysmex Buys OGT To Add Cytogenics Capability
Executive Summary
Oxford Gene Technology announced May 31 that it will become a wholly owned subsidiary of Sysmex, the Japanese in vitro diagnostics company that will gain entry into the cytogenetics market with OGT's fluorescence in situ hybridization and array comparative genomic hybridization products.
You may also be interested in...
Minute Insight: Enovis Buys Lima To Create Billion-Dollar Recon Business
Enovis has agreed to buy Italian orthopedic implant manufacturer Lima from a private equity firm for €800m – about $845m. The deal will expand Enovis’ presence in the fast-growing international extremities market and improve its manufacturing and innovation facilities.
News We're Watching: Studies Back Nevro Pain Treatment, FTC Blesses Resonetics Nitinol Deal, Genetic Test Identifies Best RDN Patients
This week, studies supported Nevro’s spinal cord stimulation therapy and a VRx system that helps reduce pain; the American Medical Association found inconsistent insurance coverage of digital therapeutics; and Geneticure announced a cheek-swab test to identify which patients are most likely to benefit from renal denervation.
Boston Scientific Puts Charge In Neuromodulation Business By Acquiring Relievant
Relievant’s Intracept intraosseous nerve ablation system is the only FDA-cleared neuromodulation device indicated to treat vertebrogenic pain. Boston Scientific will pay $850m for Relievant, plus undisclosed milestone payments over the next three years.